Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 53
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Nucleosides Nucleotides Nucleic Acids ; 23(8-9): 1117-8, 2004 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-15571212

RESUMEN

A single oral dose of 20 mg febuxostat was administered to subjects with normal, mild or moderate impairment in renal function. There was less than a 2-fold difference in AUC of plasma unchanged febuxostat among the renal function groups, and changes in plasma urate levels from pre-dose levels were not significant. A total of five adverse events were reported with all mild in severity. The results indicate that renal impairment will have little clinical impact on the pharmacokinetics (PK), pharmacodynamics (PD) and safety of the study drug.


Asunto(s)
Enfermedades Renales/tratamiento farmacológico , Tiazoles/farmacocinética , Xantina Oxidasa/antagonistas & inhibidores , Área Bajo la Curva , Inhibidores Enzimáticos/efectos adversos , Inhibidores Enzimáticos/farmacocinética , Febuxostat , Femenino , Humanos , Riñón/efectos de los fármacos , Masculino , Insuficiencia Renal/tratamiento farmacológico , Tiazoles/efectos adversos , Tiazoles/uso terapéutico , Factores de Tiempo
2.
Nucleosides Nucleotides Nucleic Acids ; 23(8-9): 1119-22, 2004 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-15571213

RESUMEN

The diurnal change of sUA and the effect of febuxostat on this change were investigated in 10 patients with gout and/or hyperuricemia. The diurnal sUA change after the last dose during the 4-week treatment phase (20 mg, QD) was almost the same as the pre-treatment value. Considering the dose, the AUC(obs) and Cmax of unchanged drug in patients with gout and/or hyperuricemia were estimated to be similar to those of healthy male adults. The results show that a 6-week treatment with febuxostat is safe and well-tolerated in the target patient population for this drug.


Asunto(s)
Inhibidores Enzimáticos/farmacocinética , Inhibidores Enzimáticos/uso terapéutico , Gota/tratamiento farmacológico , Hiperuricemia/tratamiento farmacológico , Tiazoles/farmacocinética , Tiazoles/uso terapéutico , Área Bajo la Curva , Febuxostat , Humanos , Masculino , Oxígeno/metabolismo , Factores de Tiempo , Xantina Deshidrogenasa/antagonistas & inhibidores , Xantina Oxidasa/antagonistas & inhibidores
3.
Bone ; 33(1): 90-9, 2003 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-12919703

RESUMEN

Because accumulating evidence has shown that bisphosphonates are unable to maintain their bone-sparing effects after the withdrawal of the drug, a replacement treatment is needed when bisphosphonate treatment cannot be continued for some reason. The present study investigated the preventive effects of alendronate followed by 1alpha(OH)D3 on the mass and mechanical strength of trabecular and cortical bones in ovariectomized rats. Sprague-Dawley rats were ovariectomized or sham-operated at 48 weeks of age. Ovariectomized rats treated with vehicle alone (OVX group) showed significant decreases in bone mineral density (BMD) and mechanical strength of the lumbar vertebra and the midfemur during a 20-week period after the operation as compared with sham-operated rats. These decreases were prevented by continuous treatment with alendronate (0.5 mg/kg/day, po) for 20 weeks (ALN-C group), whereas the values reverted to those of the OVX group when alendronate was withdrawn at 10 weeks (ALN-W group). The sequential treatment with alendronate and 1alpha(OH)D3 (0.05 microg/kg/day, po) for 10 weeks each (ALN --> 1alpha group) resulted in higher BMD and mechanical strength of the lumbar vertebra and the midfemur in this group than in the OVX and ALN-W groups. The increase in mechanical strength was proportional to that in BMD at both sites, suggesting that the stimulatory effects of these treatments on bone strength were due to those on bone mass. Analyses of histology, computed tomography, and biochemical markers confirmed the preventive effects of the sequential treatment. Therefore, we propose that 1alpha(OH)D3 may be a good choice to replace alendronate when alendronate treatment cannot be continued for some reason.


Asunto(s)
Alendronato/farmacología , Densidad Ósea/efectos de los fármacos , Osteoporosis/prevención & control , Ovariectomía , Vitamina D/análogos & derivados , Vitamina D/farmacología , Envejecimiento/efectos de los fármacos , Envejecimiento/metabolismo , Alendronato/uso terapéutico , Animales , Densidad Ósea/fisiología , Fuerza Compresiva/efectos de los fármacos , Fuerza Compresiva/fisiología , Quimioterapia Combinada , Femenino , Osteoporosis/tratamiento farmacológico , Osteoporosis/metabolismo , Ratas , Ratas Sprague-Dawley , Vitamina D/uso terapéutico
4.
Scand J Gastroenterol ; 37(5): 555-60, 2002 May.
Artículo en Inglés | MEDLINE | ID: mdl-12059057

RESUMEN

BACKGROUND: The role of mast cells in Crohn disease (CD) remains to be established. The aim of this study was to elucidate this in the development of CD-like colitis in rats by the use of mast-cell-deficient Ws/Ws and their control W+/W+ rats. METHODS: CD-like colitis was induced in both groups by an enema of 10 mg of 2,4, 6-trinitrobenzene sulfonic acid (TNBS) in 50% ethanol. Colonic damage, adhesion and colonic weight were measured at 7 and 14 days after the TNBS/ethanol enema. Rat mast cell protease-2 (RMCP-2) in the colonic tissue was also measured at 7 days after the enema. RESULTS: There was no significant difference between W+/W+ and Ws/Ws rats in terms of colonic damage, adhesion or colonic weight. The tissue content of RMCP-2 in Ws/Ws rats treated with either saline or TNBS/ethanol was only maintained at a much lower level than that in W+/W+ rats with the corresponding treatment. CONCLUSIONS: These results demonstrate that mast cells are not essential in the development of 2, 4, 6-trinitrobenzene sulfonic acid-induced colitis in rats.


Asunto(s)
Enfermedad de Crohn/inducido químicamente , Enfermedad de Crohn/inmunología , Mastocitos/inmunología , Ácido Trinitrobencenosulfónico/farmacología , Animales , Quimasas , Colitis/inducido químicamente , Colitis/inmunología , Colon/metabolismo , Masculino , Mastocitos/fisiología , Modelos Animales , Ratas , Serina Endopeptidasas/metabolismo
5.
Science ; 291(5512): 2411-3, 2001 Mar 23.
Artículo en Inglés | MEDLINE | ID: mdl-11264537

RESUMEN

Length determination in biology generally uses molecular rulers. The hook, a part of the flagellum of motile bacteria, has an invariant length. Here, we examined hook length and found that it was determined not by molecular rulers but probably by the amount of subunit protein secreted by the flagellar export apparatus. The export apparatus shares common features with the type III virulence-factor secretion machinery and thus may be used more widely in length determination of structures other than flagella.


Asunto(s)
Proteínas Bacterianas/metabolismo , Flagelos/ultraestructura , Flagelina/metabolismo , Salmonella typhimurium/ultraestructura , Sitios de Unión , Flagelos/metabolismo , Flagelos/fisiología , Genes Bacterianos , Microscopía Electrónica , Movimiento , Mutación , Transporte de Proteínas , Salmonella typhimurium/genética , Salmonella typhimurium/metabolismo , Salmonella typhimurium/fisiología
6.
Eur J Immunol ; 30(12): 3363-70, 2000 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-11093153

RESUMEN

We investigated the expression of peroxisome proliferator-activated receptors (PPAR) in human cultured mast cells (HCMC) by using the reverse transcription-polymerase chain reaction. HCMC expressed mRNA of PPARbeta, gamma1, and gamma2 constitutively, whereas PPARalpha was not detected. Though PPARgamma2 was expressed weakly, activation of HCMC with anti-IgE after IgE sensitization or with calcium ionophore plus phorbol ester resulted in increased expression of PPARgamma2 specifically. These stimuli did not influence the expression of PPARalpha and beta. In addition, provocation of HCMC with IgE or with IL-4 increased the mRNA level of PPARgamma2, and a synergistic effect was observed with the combination of IgE plus IL-4. To investigate a possible role of PPAR in mast cells, we examined the effects of PPAR agonists on cytokine production by HCMC. Prostaglandin (PG) D(2), Delta(12)-PGJ(2), 15deoxy-Delta(12, 14)-PGJ(2) (15d-PGJ(2)), and troglitazone, all of which are PPARgamma agonists, attenuated the production of granulocyte-macrophage colony-stimulating factor by anti-IgE-stimulated HCMC. A similar effect was observed with carbaprostacyclin, a PPARbeta agonist, but not with PPARalpha agonists. Anti-IgE-induced expression of cytokine mRNA, such as TNF-alpha, IL-5 and macrophage inflammatory protein-1alpha mRNA, was also reduced by the treatment with these PPARgamma agonists. Though only Delta(12)-PGJ(2) and 15d-PGJ(2) revealed an inhibitory effect on histamine release, leukotriene C(4) release from HCMC was suppressed by all tested PPARgamma agonists. These results indicate that HCMC express PPARbeta and gamma1/2, which might negatively regulate the activation of HCMC.


Asunto(s)
Mastocitos/fisiología , Receptores Citoplasmáticos y Nucleares/fisiología , Factores de Transcripción/fisiología , Anticuerpos Antiidiotipos/inmunología , Células Cultivadas , Factor Estimulante de Colonias de Granulocitos y Macrófagos/biosíntesis , Humanos , Mastocitos/química , Prostaglandina D2/fisiología , Receptores Citoplasmáticos y Nucleares/análisis , Factores de Transcripción/análisis
7.
Arzneimittelforschung ; 50(9): 809-15, 2000 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-11050697

RESUMEN

Protein C is the zymogen of an anticoagulant serine protease and is converted to its active form (activated protein C: APC) by thrombin in the presence of thrombomodulin. APC plays an important role in regulating coagulation and fibrinolysis by inactivating not only blood coagulation factors Va and VIIIa but also type-1 plasminogen activator inhibitor (PAI-1). The aim of the present study was to examine the effect of a human APC product (designated as CTC-111), compared with that of heparin, on the disseminated intravascular coagulation (DIC) induced by lipopolysaccharide (LPS) in rats. LPS (1 mg/kg/h) infusion was performed through a femoral vein for 4 h. One-fifth amount of the total dosage of CTC-111 or heparin was injected into the other femoral vein, followed by a 4-h infusion of the remainder. Both CTC-111 (10,000-100,000 U/kg) and heparin (400-800 IU/kg) inhibited the decrease in platelet count and fibrinogen level equally. The prolonged activated partial thromboplastin time and prothrombin time observed in DIC rats were further elongated in both CTC-111- and heparin-treated rats. But, this prolongation was less in CTC-111-treated rats than in the heparin-treated ones. Heparin inhibited the increase in fibrin and fibrinogen degradation products more prominently than CTC-111. On the other hand, CTC-111 strongly inhibited the increase in PAI-1 activity but heparin did not. These results suggest that CTC-111 may enhance fibrinolysis through its direct inhibitory effect on PAI-1. The parameters for liver or renal damage, i.e., plasma glutamic-oxaloacetic transaminase (GOT), glutamic-pyruvic transaminase (GPT), creatinine (Cre) and blood urea nitrogen (BUN), were significantly increased by LPS infusion. Both CTC-111 (100,000 U/kg) and heparin (800 IU/kg) decreased the increase in GOT and GPT levels significantly, whereas neither affected the increase in Cre or BUN. From these results, the activation of the blood coagulation system might partially contribute to the progression of liver damage caused by LPS, and might be less involved in the progression of renal damage in this model. In conclusion, CTC-111 showed both anticoagulant and profibrinolytic activity in the LPS-induced DIC model without excessive prolongation of coagulation time. From these results, CTC-111 is expected to be a useful remedy for DIC without the risk of bleeding.


Asunto(s)
Coagulación Intravascular Diseminada/prevención & control , Lipopolisacáridos/antagonistas & inhibidores , Proteína C/farmacología , Animales , Anticoagulantes/farmacología , Conducta Animal/efectos de los fármacos , Coagulación Intravascular Diseminada/inducido químicamente , Enzimas/sangre , Fibrinógeno , Heparina/farmacología , Humanos , Lipopolisacáridos/toxicidad , Pruebas de Función Hepática , Masculino , Tiempo de Tromboplastina Parcial , Recuento de Plaquetas , Tiempo de Protrombina , Ratas , Ratas Sprague-Dawley
8.
Arzneimittelforschung ; 50(8): 695-9, 2000 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-10994152

RESUMEN

Protein C (PC) is the zymogen of an anticoagulant serine protease and is converted to its active form (activated protein C: APC) by thrombin in the presence of thrombomodulin. APC plays an important role in regulating blood coagulation and fibrinolysis by inhibiting not only blood coagulation factors Va and VIIIa but also type-1 plasminogen activator inhibitor (PAI-1). In this study, it was reported that the antithrombotic effect of a human APC product (designated as CTC-111) compared with that of heparin and human PC on the deep venous thrombosis (DVT) model induced in mice by stasis caused by inferior vena cava ligation and operative invasion. Drugs were injected into a tail vein at -2, 30, 60, and 120 min after the inferior vena cava ligation. One-fifth amount of the total dosage of a given drug was injected at each time point. The wet weight of thrombus formed was reduced by APC or heparin administration, however, PC, which was equal to APC in protein amount, did not show any antithrombotic effect. To confirm whether human PC could be activated by mouse thrombin, PC was treated with mouse or human thrombin to measure the amount of APC formed. Mouse thrombin could activate human PC at a similar activation rate as human thrombin. These results suggest that externally administrated PC cannot exhibit antithrombotic effect in this DVT model due to slow activation rate to APC and that APC is a better antithrombic agent than PC for treating thrombotic diseases.


Asunto(s)
Fibrinolíticos/farmacología , Proteína C/farmacología , Trombosis de la Vena/fisiopatología , Animales , Anticoagulantes/farmacología , Heparina/farmacología , Humanos , Técnicas In Vitro , Ligadura , Masculino , Ratones , Ratones Endogámicos ICR , Tiempo de Tromboplastina Parcial , Vena Cava Inferior/fisiología
9.
Nihon Yakurigaku Zasshi ; 115(5): 295-308, 2000 May.
Artículo en Japonés | MEDLINE | ID: mdl-10872181

RESUMEN

Antiarrhythmic effects and cardiovascular effects of pilsicainide hydrochloride were compared with those of disopyramide in a canine model of coronary ligation-induced ventricular arrhythmias and anesthetized dogs. Pilsicainide (1.25, 2.5 and 5 mg/kg) and disopyramide (2.5 and 5 mg/kg) decreased the arrhythmic ratio ¿(ventricular arrhythmias/total heart rate) x 100¿ dose-dependently. Pilsicainide at 2.5 and 5 mg/kg and disopyramide at 5 mg/kg suppressed ventricular arrhythmias more than 50%. The effective dose of pilsicainide was lower than that of disopyramide, but the effective plasma concentration of pilsicainide was between 3 and 8 micrograms/ml, which was almost the same as that of disopyramide. In anesthetized dogs, both drugs decreased LV dP/dt max in almost the same concentration-dependent manner. PQ-interval was prolonged by pilsicainide, but not by disopyramide. QRS and QTc were prolonged by both drugs in a concentration-dependent manner. However, the prolongation of QTc by disopyramide was provoked at lower plasma concentrations than by pilsicainide. Because the excessive prolongation of QTc lead to the lethal arrhythmias such as torsades de pointes, pilsicainide may be useful as an injectable antiarrhythmic agent superior to disopyramide.


Asunto(s)
Antiarrítmicos/administración & dosificación , Arritmias Cardíacas/tratamiento farmacológico , Disopiramida/administración & dosificación , Electrocardiografía/efectos de los fármacos , Hemodinámica/efectos de los fármacos , Lidocaína/análogos & derivados , Anestesia , Animales , Antiarrítmicos/farmacología , Vasos Coronarios , Modelos Animales de Enfermedad , Disopiramida/farmacología , Perros , Relación Dosis-Respuesta a Droga , Femenino , Infusiones Intravenosas , Lidocaína/administración & dosificación , Lidocaína/farmacología , Ligadura
10.
J Vet Med Sci ; 62(5): 537-8, 2000 May.
Artículo en Inglés | MEDLINE | ID: mdl-10852406

RESUMEN

Using the triple-stain technique, we investigated whether sperm acrosomes in frozen canine semen were protected during freezing and thawing by addition of a surfactant, Orvus ES Paste (OEP), to the extender. Acrosomes were clearly shown to be protected by the addition of OEP to the entender when compared with those in sperm frozen without OEP addition (p<0.05).


Asunto(s)
Acrosoma/efectos de los fármacos , Criopreservación/veterinaria , Perros/fisiología , Preservación de Semen/veterinaria , Tensoactivos/farmacología , Acrosoma/fisiología , Animales , Criopreservación/métodos , Masculino , Semen/fisiología , Preservación de Semen/métodos , Motilidad Espermática/fisiología
11.
Life Sci ; 66(21): 2051-70, 2000 Apr 14.
Artículo en Inglés | MEDLINE | ID: mdl-10823345

RESUMEN

We investigated the relationship between the toxic effect of allopurinol and pyrimidine metabolism in mice. Allopurinol-induced increases in plasma transaminase levels in dinitrofluorobenzene (DNFB)-sensitized mice were not affected by uridine. In contrast, plasma creatinine and BUN tended to decrease 18 hr after the last injection of uridine. Both plasma and urinary orotidine (OD) were detected in DNFB-sensitized mice after administration of a single dose of allopurinol. In contrast, TEI-6720, a newly synthesized xanthine oxidase/xanthine dehydrogenase inhibitor, caused neither pyrimidine metabolism abnormality nor renal impairment in DNFB-sensitized mice. Also, normal mice administered high doses of allopurinol showed abnormal pyrimidine metabolism together with renal toxicity which could be ameliorated by uridine, indicating that allopurinol essentially causes pyrimidine metabolism abnormality leading to renal impairment. In DNFB-sensitized mice, allopurinol increased urinary OD excretion to an extent similar to that in normal mice administered the same dose of allopurinol. However, renal impairment by allopurinol was more striking in DNFB-sensitized mice than in normal mice. Histopathological observations showed that allopurinol induced calculus formation in the collecting tubules and papillary duct. Calculus formation was increased by DNFB and decreased by uridine. These observations indicate that the enhancement of the renal toxicity of allopurinol by DNFB-sensitization may be due to some biological interactions between DNFB and allopurinol. In humans, it is possible that there are some biological interactions which serve to enhance the toxicity of allopurinol, resulting in the development of allopurinol hypersensitivity syndrome (AHS). In contrast, TEI-6720, had no effect on pyrimidine metabolism and showed no toxic effect.


Asunto(s)
Alopurinol/toxicidad , Antimetabolitos/toxicidad , Riñón/efectos de los fármacos , Pirimidinas/metabolismo , Animales , Dinitrofluorobenceno/farmacología , Hipersensibilidad a las Drogas , Interacciones Farmacológicas , Riñón/metabolismo , Enfermedades Renales/inducido químicamente , Enfermedades Renales/metabolismo , Masculino , Ratones , Ratones Endogámicos BALB C , Uridina/farmacología
12.
Am J Physiol Regul Integr Comp Physiol ; 278(4): R863-9, 2000 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-10749773

RESUMEN

Menopausal hot flushes (HFs), which manifest as an increase in skin temperature, most frequently occur after menopause and cease with the passage of time. We designed this study to elucidate the characteristics of the elevation of tail skin temperature (TST) in ovariectomized (OVX) rats, which is relevant to human symptoms of HFs. First, we measured TST and rectal temperature (RT) and investigated the time course of their changes up to 20 wk after ovariectomy. The TST in OVX rats (28.4 +/- 0.3 degrees C) was significantly (P = 0.0035) elevated from 2 to 7 wk after the ovariectomy compared with that in sham-operated (Sham) rats (27.0 +/- 0.2 degrees C), whereas the RT in OVX rats was elevated from 8 to 20 wk. We next examined the therapeutic effects of estradiol (E(2)) on the elevation of the TST by continuous subcutaneous infusion. E(2) treatment (1.0 microg/day) completely (P = 0.0232) inhibited the elevation of the TST (28.4 +/- 0.3 degrees C for Sham rats, 29.3 +/- 0.3 degrees C for OVX rats, 28.2 +/- 0.4 degrees C for OVX + E(2) 1.0 microg/day rats). These results demonstrated that the elevation of TST in OVX rats was exhibited soon after the estrogen removal and diminished with time and that it was normalized with continuous E(2) replacement. These characteristics are similar to the symptoms of menopausal HFs in women.


Asunto(s)
Regulación de la Temperatura Corporal/fisiología , Menopausia/fisiología , Ovariectomía , Temperatura Cutánea/fisiología , Animales , Regulación de la Temperatura Corporal/efectos de los fármacos , Estradiol/farmacología , Femenino , Humanos , Inyecciones Subcutáneas , Ratas , Ratas Sprague-Dawley , Temperatura Cutánea/efectos de los fármacos , Organismos Libres de Patógenos Específicos , Cola (estructura animal)
13.
FEBS Lett ; 467(2-3): 259-62, 2000 Feb 11.
Artículo en Inglés | MEDLINE | ID: mdl-10675550

RESUMEN

We examined the expression of peroxisome proliferator-activated receptors (PPARs) and the role of PPARs in cytokine production in mouse bone marrow-derived mast cells (mBMMCs). mBMMCs expressed PPARbeta strongly and gamma slightly, but not alpha. Activation of mBMMCs with antigen or calcium ionophore resulted in the increased expression of PPARgamma mRNA specifically. 15-Deoxy-Delta(12, 14)-prostaglandin J(2) (15d-PGJ(2)) and troglitazone, all PPARgamma ligands, attenuated the antigen-induced cytokine production by mBMMCs. Carbaprostacyclin, a PPARbeta ligand, also inhibited cytokine production, whereas PPARalpha ligands did not. These results suggest that PPARbeta and gamma might be included in the negative regulation of mast cell activation.


Asunto(s)
Células de la Médula Ósea/metabolismo , Mastocitos/metabolismo , Receptores Citoplasmáticos y Nucleares/metabolismo , Tiazolidinedionas , Factores de Transcripción/metabolismo , Animales , Células de la Médula Ósea/efectos de los fármacos , Células Cultivadas , Cromanos/farmacología , Citocinas/metabolismo , Femenino , Liberación de Histamina/efectos de los fármacos , Ligandos , Mastocitos/efectos de los fármacos , Ratones , Ratones Endogámicos BALB C , Prostaglandina D2/análogos & derivados , Prostaglandina D2/farmacología , Tiazoles/farmacología , Troglitazona
14.
Ultrasound Med Biol ; 26(1): 161-6, 2000 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-10687804

RESUMEN

It has been shown that low-intensity pulsed ultrasound (US) accelerates fracture healing in animal models and in clinical studies. However, the mechanism by which US accelerates fracture healing remains unclear. Systemic factors and several growth factors, such as platelet-derived growth factor (PDGF), are thought to be involved in the process of fracture healing. In the present study, we examined the effects of US and 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] on growth factor secretion in a co-culture system of human osteoblastic cells (SaOS-2) and endothelial cells (HUVEC). US was applied to cultured cells for 20 min daily for four consecutive days. US treatment increased the PDGF-AB level in the conditioned media. 1,25-(OH)2D3 (1 x 10(-8) M) also enhanced PDGF-AB secretion. The secretion of PDGF-AB was synergistically increased by the combination of US and 1,25-(OH)2D3. These results suggest that the stimulation of growth factor secretion from cells by US and 1,25-(OH)2D3 treatment may be involved in the acceleration of fracture healing.


Asunto(s)
Calcitriol/farmacología , Agonistas de los Canales de Calcio/farmacología , Factores de Crecimiento Endotelial/metabolismo , Endotelio/metabolismo , Osteoblastos/metabolismo , Ultrasonido , Análisis de Varianza , Técnicas de Cocultivo , Endotelio/efectos de los fármacos , Curación de Fractura/fisiología , Humanos , Osteoblastos/efectos de los fármacos , Venas Umbilicales/citología
15.
Jpn J Physiol ; 50(6): 651-6, 2000 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-11173561

RESUMEN

We examined the effects of progesterone on the elevation of tail skin temperature (TST) in ovariectomized rats and compared them with those of estradiol. Progesterone showed only insignificant effects on the TST elevation, whereas estradiol showed complete inhibition. The TST elevation induced by ovariectomy is caused by estradiol deficiency, but progesterone plays little or no role.


Asunto(s)
Temperatura Corporal/fisiología , Estradiol/fisiología , Progesterona/fisiología , Piel , Animales , Temperatura Corporal/efectos de los fármacos , Estradiol/farmacología , Femenino , Ovariectomía , Progesterona/farmacología , Ratas , Ratas Sprague-Dawley , Cola (estructura animal)
16.
Mol Microbiol ; 34(4): 767-79, 1999 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-10564516

RESUMEN

We analysed all major proteins secreted into culture media from Salmonella typhimurium. Proteins in culture supernatants were collected by trichloroacetic acid precipitation, separated in SDS-polyacrylamide gels and analysed by amino acid sequencing. Wild-type strain SJW1103 cells typically gave rise to nine bands in SDS gels: 89, 67, 58, 52, 50, 42, 40, 35 and (sometimes) 28 kDa. A search of the sequences in the available databases revealed that they were either flagellar proteins or virulence factors. Six of them were flagella specific: FlgK or HAP1 (58 kDa), FliC or flagellin (52 kDa), FliD or HAP2 (50 kDa), FlgE or hook protein (42 kDa), FlgL or HAP3 (35 kDa) and FlgD or hook-cap protein (28 kDa). The other four bands were specific for virulence factors: SipA (89 kDa), SipB (67 kDa), SipC (42 kDa) and InvJ (40 kDa). The 42 kDa band was a mixture of FlgE and SipC. We also analysed secreted proteins from more than 30 flagellar mutants, and they were categorized into four groups according to their band patterns: wild type, mot type, polyhook type and master gene type. Virulence factors were constantly secreted at a higher level in all flagellar mutants except a deltamot (motAB deletion) mutant, in which the amounts were greatly reduced. A new morphological pathway of flagellar biogenesis including protein secretion is presented.


Asunto(s)
Proteínas Bacterianas/metabolismo , Flagelos/metabolismo , Flagelina/metabolismo , Proteínas de Microfilamentos , Salmonella typhimurium/metabolismo , Actinas/química , Actinas/aislamiento & purificación , Proteínas Bacterianas/química , Proteínas Bacterianas/genética , Proteínas Bacterianas/aislamiento & purificación , Medios de Cultivo , Electroforesis en Gel de Poliacrilamida , Flagelos/fisiología , Flagelina/química , Flagelina/genética , Flagelina/aislamiento & purificación , Proteínas de la Membrana/química , Proteínas de la Membrana/aislamiento & purificación , Mutación , Salmonella typhimurium/genética , Análisis de Secuencia , Virulencia
17.
Biol Pharm Bull ; 22(8): 810-5, 1999 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-10480318

RESUMEN

The immunomodulatory effects of allopurinol were investigated in a mouse contact hypersensitivity model. Allopurinol caused a time- and dose-dependent lethal effect in dinitrofluorobenzene (DNFB)-sensitized mice. Furthermore, allopurinol markedly increased ear swelling in the remaining mice. In contrast, TMX-67, a newly synthesized xanthine oxidase/xanthine dehydrogenase (XOD/XDH) inhibitor, had almost no effect on DNFB-sensitized mice. Allopurinol reduced both the spleen weight and white blood cell count in DNFB-sensitized mice without affecting the T cell subset of splenocytes. The production of interferon (IFN)-gamma, in the splenocytes of DNFB-sensitized mice was reduced by allopurinol administration. Death due to allopurinol was much lower in the non-sensitized mice than in the DNFB-sensitized mice. These findings indicate that allopurinol may interact with DNFB to enhance its toxicity and allopurinol might also modulate or enhance the inflammatory effect of DNFB. Also, DNFB may cause metabolic alterations via inflammation, leading to enhanced allopurinol toxicity.


Asunto(s)
Alopurinol/farmacología , Dermatitis por Contacto/fisiopatología , Dinitrofluorobenceno/toxicidad , Oído/fisiopatología , Animales , Citocinas/metabolismo , Dermatitis por Contacto/metabolismo , Dermatitis por Contacto/mortalidad , Modelos Animales de Enfermedad , Citometría de Flujo , Masculino , Ratones , Ratones Endogámicos BALB C , Tasa de Supervivencia
18.
J Leukoc Biol ; 65(6): 744-9, 1999 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-10380894

RESUMEN

Chemokines have been shown to play an important role in leukocyte infiltration into ischemic lesions. Recently, the increased expression of monocyte chemoattractant protein-1 (MCP-1) and cytokine-induced neutrophil chemoattractant (CINC) was observed in experimental stroke models where infiltrated leukocytes were supposed to induce tissue injury, however, the protein level and time course of these chemokines have not been fully elucidated. Therefore, we analyzed the time-dependent production of MCP-1 and CINC in the rat brain after transient middle cerebral artery occlusion (MCAO) by means of specific enzyme-linked immunosorbent assay systems. The MCP-1 levels in the ipsilateral hemispheres increased from 6 h, peaked at 2 days, and thereafter gradually decreased. The peak MCP-1 concentration was 89.2+/-28.2 ng/g tissue wet weight (mean +/- SEM, n = 5, 49.3-fold greater than the contralateral value at the same time, P < 0.05), which is supposed to be high enough to exert its biological effects. In contrast, the maximum CINC concentration that corresponded to 2.9+/-0.7 ng/g tissue wet weight (mean +/- SEM, n = 5, 55.0-fold greater than the contralateral value at the same time, P < 0.05), was observed at 6 h. In addition, we confirmed the temporal profile of leukocyte subtypes that infiltrated into the ischemic brain, thus, neutrophil infiltration occurred at early stages (1-3 days), followed by massive infiltration of macrophages at later stages (2-7 days). These studies suggest that MCP-1 in cerebral ischemia actually plays a significant role in the migration of macrophages into the lesion and that the differential temporal production of these chemokines contributes to the regulation of infiltrated leukocyte subtypes.


Asunto(s)
Isquemia Encefálica/metabolismo , Quimiocina CCL2/biosíntesis , Factores Quimiotácticos/biosíntesis , Sustancias de Crecimiento/biosíntesis , Péptidos y Proteínas de Señalización Intercelular , Ataque Isquémico Transitorio/complicaciones , Animales , Quimiocinas CXC/metabolismo , Modelos Animales de Enfermedad , Leucocitos/citología , Macrófagos/citología , Masculino , Ratas , Ratas Wistar
19.
Res Commun Mol Pathol Pharmacol ; 104(3): 293-305, 1999.
Artículo en Inglés | MEDLINE | ID: mdl-10741380

RESUMEN

Allopurinol is widely used and generally well-tolerated. However, when used in patients with renal insufficiency it may have life-threatening toxic effects known as allopurinol hypersensitivity syndrome (AHS). We previously found that allopurinol increased ear swelling and mortality in a DNFB-induced contact hypersensitivity mouse model. In the present study, we investigated the toxic effect of allopurinol on DNFB-sensitized mice in order to clarify the mechanism responsible for the lethal effect of allopurinol. Allopurinol increased plasma GPT and GOT in DNFB-sensitized mice and markedly increased plasma creatinine and BUN. The increase in plasma GPT and GOT was moderate and declined time-dependently. In contrast, the increase in plasma creatinine and BUN was striking and continued until 18 hr after administration of allopurinol at 100 mg/kg/day. Although allopurinol increased GOT and GPT in DNFB-sensitized mice, no effect was observed in non-sensitized mice even at 100 mg/kg/day, indicating that allopurinol essentially has no toxic effect on the liver. A high dose of allopurinol induced renal impairment even in non-sensitized mice. These observations indicate that there is some biological interaction between allopurinol and DNFB, and suggest that allopurinol may modulate or enhance the inflammatory reactions induced by DNFB, and/or that DNFB may cause metabolic changes via inflammation, leading to the enhanced toxicity of allopurinol. In contrast, TEI-6720, a newly synthesized XOD/XDH inhibitor, had almost no effect on DNFB-sensitized mice. TEI-6720 at 1 mg/kg, in terms of hypouricemic effect, appeared to be more potent than allopurinol at 3 mg/kg. Therefore, the nephrotoxic effect of allopurinol observed in the present study may not be related to XOD/XDH inhibitory activity.


Asunto(s)
Lesión Renal Aguda/inducido químicamente , Alopurinol/toxicidad , Dermatitis por Contacto/patología , Inhibidores Enzimáticos/toxicidad , Xantina Oxidasa/antagonistas & inhibidores , Lesión Renal Aguda/sangre , Animales , Nitrógeno de la Urea Sanguínea , Creatinina/sangre , Dermatitis por Contacto/sangre , Dermatitis por Contacto/etiología , Dinitrofluorobenceno , Febuxostat , Hígado/enzimología , Masculino , Ratones , Ratones Endogámicos BALB C , Tiazoles/toxicidad
20.
Res Commun Mol Pathol Pharmacol ; 104(3): 307-19, 1999.
Artículo en Inglés | MEDLINE | ID: mdl-10741381

RESUMEN

In this study, the hypouricemic efficacy of a novel xanthine oxidase/xanthine dehydrogenase inhibitor, TEI-6720, was compared with that of allopurinol in a hyperuricemic rat model established by feeding the animals oxonate, a uricase inhibitor. In addition, using normal rats, the changes in xanthine concentration in plasma and the concentrations and absolute quantities of uric acid, allantoin and xanthine in urine were analyzed during a 28-day period of repeated administration of TEI-6720 to determine the changes occurring during this period and the conditions required for the formation of xanthine crystals and calculi in comparison with allopurinol. TEI-6720 and allopurinol caused a significant dose-dependent decrease in plasma uric acid levels in the hyperuricemic rat model and the ED50 of TEI-6720 was lower than that of allopurinol, indicating that in terms of hypouricemic efficacy TEI-6720 is more potent than allopurinol. TEI-6720 also showed more potent activity than allopurinol in decreasing urinary uric acid and allantoin levels in normal rats. In addition, TEI-6720 and allopurinol showed similar dose-response curves for the decrease in uric acid or allantoin concentration, and the associated increase in xanthine concentration, indicating that TEI-6720 and allopurinol have similar pharmacological characteristics although the dosage required differs. The efficacy of TEI-6720 in increasing plasma and urinary xanthine levels in normal rats was approximately 10- to 30-fold greater than that of allopurinol. However, with respect to renal xanthine calculus formation, there was only about a 3-fold difference in dosage comparing TEI-6720 and allopurinol. This difference suggests that there may be another factor independent of xanthine, and dependent on the drug itself, involved in renal calculus formation caused by allopurinol. The daily excretion of purine metabolites per body weight was about 20-fold higher in rats than in humans. From these results, it is concluded that TEI-6720 has potent hypouricemic activity and that, compared to allopurinol, administration of TEI-6720 is not likely to result in a higher incidence of calculus formation.


Asunto(s)
Alopurinol/farmacología , Inhibidores Enzimáticos/farmacología , Cálculos Renales/inducido químicamente , Tiazoles/farmacología , Ácido Úrico/sangre , Xantina Oxidasa/antagonistas & inhibidores , Xantina/sangre , Alantoína/orina , Alopurinol/efectos adversos , Animales , Inhibidores Enzimáticos/efectos adversos , Febuxostat , Cálculos Renales/química , Masculino , Ratas , Ratas Endogámicas , Tiazoles/efectos adversos , Ácido Úrico/orina , Xantina/química , Xantina/orina
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...